RE:DilutionsThey should merge with some cash rich biotech like Repare Therapeutics that has 225M in cash and just lost its onco partner not so long ago. A merge of equals could pay the dept and provide them with sales and another onco program. Just saying instead of pursuing a business plan that switched around from biotech to specialty pharma to a mix of both to specialty pharma again with a partner for onco and nash. No clear business plan and a huge waste of money for nothing excepet a pile of dept.